Inhaled Medicines for Targeting Non-Small Cell Lung Cancer
Throughout the years, considerable progress has been made in methods for delivering drugs directly to the lungs, which offers enhanced precision in targeting specific lung regions. Currently, for treatment of lung cancer, the prevalent routes for drug administration are oral and parenteral. These me...
Main Authors: | Arwa Omar Al Khatib, Mohamed El-Tanani, Hisham Al-Obaidi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/12/2777 |
Similar Items
-
Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges
by: Wing-Hin Lee, et al.
Published: (2015-12-01) -
Correction: Al Khatib et al. Inhaled Medicines for Targeting Non-Small Cell Lung Cancer. <i>Pharmaceutics</i> 2024, <i>15</i>, 2777
by: Arwa Omar Al Khatib, et al.
Published: (2024-08-01) -
Recent advances in non-small cell lung cancer targeted therapy; an update review
by: Mahmood Araghi, et al.
Published: (2023-08-01) -
Spray-Dried Nanolipid Powders for Pulmonary Drug Delivery: A Comprehensive Mini Review
by: Mahmoud H. Abu Elella, et al.
Published: (2024-05-01) -
Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine
by: Barbara Melosky
Published: (2017-12-01)